Synopsis of a research roundtable presented on cell signaling in myeloma: Regulation of growth and apoptosis - Opportunities for new drug discovery

Molecular Cancer Therapeutics

Volumn 1, Issue 14, 2002, Pages 1361-1365

  Anderson, Kenneth C ^a   Dalton, William S ^b  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN TYROSINE KINASE;

APOPTOSIS; CELL ADHESION; CELL DIVISION; CELL SURVIVAL; DRUG ANTAGONISM; DRUG DESIGN; GENE TRANSLOCATION; HUMAN; METABOLISM; MULTIPLE MYELOMA; MUTATION; REVIEW; SIGNAL TRANSDUCTION;

APOPTOSIS; CELL ADHESION; CELL DIVISION; CELL SURVIVAL; DRUG DESIGN; HUMANS; MULTIPLE MYELOMA; MUTATION; PROTEIN-TYROSINE KINASES; SIGNAL TRANSDUCTION; TRANSLOCATION, GENETIC;

EID: 0037704263     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (28)

1. Longo, D. L. In: A. S. Fauci, E. Braunwald, K. J. Isselbacher, J. D. Wilson, J. B. Martin, D. L. Kasper, S. I. Hauser, and D. L. Longo (eds), Harrison's Principles of Internal Medicine, Ed. 14, pp. 713-716. New York: McGraw Hill, 1999.
2. Zaidi, A. A., and Vesole, D. H. Multiple myeloma: an old disease with new hope for the future. CA Cancer J. Clin., 51: 273-285, 2001. (Pubitemid 34232773)
3. Shain, K. H., Landowski, T. H., and Dalton, W. S. Adhesion-mediated intracellular redistribution of c-Fas-associated death domain-like IL-1- converting enzyme-like inhibitory protein-long confers resistance to CD95-induced apoptosis in hematopoietic cancer cell lines. J. Immunol., 168: 2544-2553, 2002. (Pubitemid 34171863)
4. Anderson, K. C., Kyle, R. A., Dalton, W. S., Landowski, T., Shain, K., Jove, R., Hazlehurst, L., and Berenson, J. Multiple myeloma: new insights and therapeutic approaches. Hematology (Am. Soc. Hematol. Educ. Program), 147-165, 2000.
5. Anderson, K. C. Targeted therapy for multiple myeloma. Semin. Hematol., 38: 286-294, 2001. (Pubitemid 32717666)
6. Drach, J., Kaufmann, H., Urbauer, E., Urbauer, E., Schreiber, S., Ackermann, J., and Huber, H. The biology of multiple myeloma. J. Cancer Res. Clin. Oncol., 126: 441-447, 2000. (Pubitemid 30483157)
7. Bergsagel, P. L., and Kuehl, W. M. Chromosome translocations in multiple myeloma. Oncogene, 20: 5611-5622, 2001.
8. Plowright, E. E., Li, Z., Bergsagel, P. L., Chesi, M., Barber, D. L., Branch, D. R., Hawley, R. G., and Stewart, A. K. Ectopic expression of fibroblast growth factor receptor 3 promotes myeloma cell proliferation and prevents apoptosis. Blood, 95: 992-998, 2000. (Pubitemid 30062723)
9. Callander, N. S., and Roodman, G. D. Myeloma bone disease. Semin. Hematol., 38: 276-285, 2001. (Pubitemid 32717665)
10. Thabard, W., Collette, M., Mellerin, M. P., Puthier, D., Barille, S., Bataille, R., and Amiot, M. IL-6 upregulates its own receptor on some human myeloma cell lines. Cytokine, 14: 352-356, 2001. (Pubitemid 32730477)
11. Cheung, W. C., and Van Ness, B. Distinct IL-6 signal transduction leads to growth arrest and death in B cells or growth promotion and cell survival in myeloma cells. Leukemia, 16: 1182-1188, 2002. (Pubitemid 34618857)
12. Catlett-Falcone, R., Landowski, T. H., Oshiro, M. M., Turkson, J., Levitzki, A., Savino, R., Ciliberto, G., Moscinski, L., Fernandez-Luna, J. L., Nunez, G., Dalton, W. S., and Jove, R. Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells. Immunity, 10: 105-115, 1999. (Pubitemid 29077388)
13. Valdembri, D., Serini, G., Vacca, A., Ribatti, D., and Bussolino, F. In vivo activation of JAK2/STAT-3 pathway during angiogenesis induced by GM-CSF. FASEB J., 16: 225-227, 2002.
14. Hideshima, T., Chauhan, D., Podar, K., Schlossman, R. L., Richardson, P., and Anderson, K. C. Novel therapies targeting the myeloma cell and its bone marrow microenvironment. Semin. Oncol., 28: 607-612, 2001. (Pubitemid 33134420)
15. Damiano, J. S., Cress A. E., Hazlehurst, L. A., Shtil, A. A., and Dalton, W. S. Cell adhesion mediated drug resistance (CAM-DR): role of integrins and resistance to apoptosis in human myeloma cell lines. Blood, 93: 1658-1667, 1999. (Pubitemid 29102494)
16. Berenson, J. R., Ma, H. M., and Vescio, R. The role of nuclear factor-kappaB in the biology and treatment of multiple myeloma. Semin. Oncol., 28: 626-633, 2001. (Pubitemid 33138161)
17. Folkman, J. Angiogenesis-dependent diseases. Semin. Oncol., 28: 536-542, 2001. (Pubitemid 33134412)
18. Gupta, D., Treon, S. P., Shima, Y., Hideshima, T., Podar, K., Tai, Y. T., Lin, B., Lentzsch, S., Davies, F. E., Chauhan, D., Schlossman, R. L., Richardson, P., Ralph, P., Wu, L., Payvandi, F., Muller, G., Stirling, D. I., and Anderson, K. C. Adherence of multiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial growth factor secretion: therapeutic applications. Leukemia, 15: 1950-1961, 2001. (Pubitemid 33115003)
19. Martinelli, G., Tosi, P., Ottaviani, E., Soverini, S., and Tura, S. Molecular therapy for multiple myeloma. Haematologica, 86: 908-917, 2001. (Pubitemid 32937699)
20. Myeloma Focus, Newsletter of the Multiple Myeloma Research Foundation. Vol. III:2, 2001.
21. Laird, A. D., Christensen, J. G., Li, G., Carver, J., Smith, K., Xin, X., Moss, K. G., Louie, S. G., Mendel, D. B., and Cherrington, J. M. SU6668 inhibits Flk-1/KDR and PDGFRbeta in vivo, resulting in rapid apoptosis of tumor vasculature and tumor regression in mice. FASEB J., 16: 681-690, 2002. (Pubitemid 34465432)
22. Klasa, R. J., Gillum, A. M., Klem, R. E., and Frankel, S. R. Oblimersen Bcl-2 antisense: facilitating apoptosis in anticancer treatment. Antisense Nucleic Acid Drug Dev., 12: 193-213, 2002. (Pubitemid 34815931)
23. Banerjee, D. Genasense (Genta Inc). Curr. Opin. Investig. Drugs, 2: 574-580, 2001.
24. Sebti, S. M., and Hamilton, A. D. Farnesyltransferase and geranylgeranyltransferase I inhibitors and cancer therapy: lessons from mechanism and bench-to-bedside translational studies. Oncogene, 19:6584-6593, 2000. (Pubitemid 32197696)
25. Gandhi, V., Ayres, M., Halgren, R. G., Krett, N. L., Newman, R. A., and Rosen, S. T. 8-chloro-cAMP and 8-chloro-adenosine act by the same mechanism in multiple myeloma cells. Cancer Res., 61: 5474-5479, 2001. (Pubitemid 32694929)
26. Schroeder, M. C., Hamby, J. M., Connolly, C. J., Grohar, P. J., Winters, R. T., Barvian, M. R., Moore, C. W., Boushelle, S. L., Crean, S. M., Kraker, A. J., Driscoll, D. L., Vincent, P. W., Elliott, W. L., Lu, G. H., Batley, B. L., Dahring, T. K., Major, T. C., Panek, R. L., Doherty, A. M., and Showalter, H. D. Soluble 2-substituted aminopyrido[2, 3-d]pyrimidin-7-yl ureas. Structure-activity relationships against selected tyrosine kinases and exploration of in vitro and in vivo anticancer activity. J. Med. Chem., 44: 1915-1926, 2001. (Pubitemid 32884516)
27. Advani, A., and Pendergast, A. Bcr-Abl variants: biological and clinical aspects. Leuk. Res., 26: 713-720, 2002. (Pubitemid 34628369)
28. Fabbro, D., Ruetz, S., Buchdunger, E., Cowan-Jacob, S., Fendrich, G., Liebetanz, J., Mestan, J., O'Reilly, T., Traxler, P., Chaudhuri, B., Fretz, H., Zimmermann, J., Meyer, T., Caravatti, G., Furet, P., and Manley, P. Protein kinases as targets for anticancer agents: from inhibitors to useful drugs. Pharmacol. Ther., 93: 79, 2002.